

INTRODUCTION TO CANCER TREATMENT : RADIATION ONCOLOGY


Waisse WAISSI MD. PhD.

Département de Radiothérapie

Centre Léon Bérard

Génétique Epigénétique et Biologie des sarcomes

Centre de Recherche en Cancérologie de Lyon



CRCL CENTRE DE
RECHERCHE EN
CANCÉROLOGIE
DE LYON

Disclosures


- None

Radiation Oncologist

What my friends think I do ?




What I really do ?



Objectives

- Understand the role of radiation therapy in cancer management.
- Recognize different radiation techniques and their clinical applications.

Introduction




In 2050, GLOBOCAN 2022 data indicated 33.1 million new cancer diagnoses, with 16.5 million new patients needing radiotherapy at an estimated use rate of 50% and 21.2 million at an estimated use rate of 64%.


Why Radiation therapy matters ?

- Radiation therapy has been a cornerstone of cancer treatment for over a century.
- Initially used for symptom relief, it evolved into a curative modality for many cancers.
- Today, it is integrated with surgery and systemic therapy for optimal outcomes.
- Advances in imaging and computing have transformed Radiotherapy to highly precise techniques.


Radiation and DNA Damage



Major DNA repair pathways and biomarkers



Treatment modalities




How to prescribe radiation in clinical setting ?

- Particle : usually Photons
- Total dose
- Dose per fraction
- Number of fraction per day/week
- Overall treatment time
- Techniques :
 - External : 3DCRT, IMRT
 - Brachytherapy

Workflow

Classical radiotherapy workflow



Multidisciplinary meeting

Consultation



- ➔ What type of radiation treatment
- ➔ What is the benefit ?
- ➔ What are the side effects ?

Treatment response evaluation
Side effects

Radiation Therapy indications


- Radiation therapy is present at all stages of the disease:
 - Exclusive: As the sole treatment modality.
 - Before surgery (Neoadjuvant): To shrink the tumor and facilitate surgery.
 - After surgery (Adjuvant): To eliminate microscopic residual disease and reduce recurrence risk.
 - In case of relapse (Re-irradiation): When cancer returns in a previously treated area.
 - In metastatic setting (Palliative): To relieve symptoms and improve quality of life.
 - In oligometastatic setting : to postpone new systemic treatment

Definitive Curative treatment : HNSCC



70 Gy in 35 fractions in the high risk area




Definitive Curative low dose radiotherapy



→ Complete response

Neo-adjuvante Curative treatment- Soft tissue sarcoma


Myxoid liposarcoma – Right lower limb






50 Gy in 25 fractions




Adjuvant curative treatment-Breast Cancer



Surgical lumpectomy




Adjuvant radiotherapy



Palliative indication-Bone metastasis

Breast Cancer multiple bone metastasis

L5 symptomatic bone metastasis : 8 Gy in one fraction






SBRT






Oligometastatic –Bone metastasis

Clear cell sarcoma : 1 bone metastasis : SBRT



Oligometastatic treatment-SBRT



Case Presentation

- Mrs L..
- 60 yo, post menopausal
- Initial presentation : December 2023, Mammogram screening shows a mass with irregular shape and spiculated margins
- Medical history : None
- Family history : None



Clinical examination

- Right breast: T0
- Lymph nodes: N0

Ultra sound guided biospies


- Right breast mass (core needle),
 - Invasive ductal carcinoma, grade 1, No LVI
 - ER+(100%)PR+(90%)Her2-
 - Ki-67 5%

Surgery and Pathology

- Right simple Lumpectomy and sentinel lymph node dissection.
Pathology:
 - Breast : 15mm, Grade 1, LVI-
 - Lymph nodes: 0/3 involved
- Stage pT1c pN0 (Stage IA, AJCC 8th Ed. Anatomic)
- Negative surgical margins

Should patient undergo Radiotherapy ?

Rationale for post lumpectomy radiotherapy



EBCTCG, Lancet, 2011




First relapse



Specific survival

PRIME II Trial

Age >65 years old
T1 or T2<3cm
N0
ER or PR +




What treatment schedule is the most appropriate ?

Fractionation




- Conventiounnal




- 2Gy/fraction
- 5-6,5 weeks

- Moderate



- >2Gy/fraction
- 3-5 weeks
- OCOG/START A-B/DBCG


- Ultra



- 5,2-5,7 Gy/fraction
- 1 week ou 5 weeks
- FAST et FAST FORWARD

FAST-FORWARD

Age >50 : 85 %
 Grade 1-2 : 72%
 Lumpectomy : 93%
 pN0 : 82%
 IDC : 80%
 <pT2 : 98 %
 ER+/HER2- : 82%
 Boost : 25%




➔ Ultra Hypofractionnation is non inferior to Moderate hypofractionnation

BRUNT AM et al. Lancet Oncol 2020

Planning

- ➔ Dose prescription : 26Gy in 5 fractions
- FAST FORWARD phase III RCT
- ➔ 2 VMAT Arc : Butterfly



Could partial Breast irradiation be an alternative ?

Partial irradiation

520 patientes



pT1-2 (<2.5 cm)
Age>40 ans

R

50Gy/25 fractions + boost




30Gy/5 fractions



Patient-rated cosmesis ^b			
Excellent	44 (17.9)	13 (5.1)	.0001
Good	200 (81.3)	209 (80.3)	
Fair	2 (0.8)	38 (14.6)	
Poor	—	—	

Meattini et al. JCO 2020

Perspectives : APBI



Goldberg et al. IJROBP 2023

Guidelines

4. Partial breast irradiation—suitable patient selection for external beam radiotherapy

I. Luminal-like subtypes small tumour (≤ 3 cm)	91.3%	Strong consensus
II. Clear surgical margins (> 2 mm)	95.6%	Strong consensus
III. Nodal status
IIIa. Node negative	100%	Unanimous consensus
IIIb. Node negative (including isolated tumour cells)	82.6%	Consensus
IV. Absence of lymph vascular space invasion	87.0%	Consensus
V. Non-lobular invasive carcinoma	87.0%	Consensus
VI. Tumour grade 1–2	91.3%	Strong consensus
VII. Low-to-intermediate grade DCIS, sized ≤ 2.5 cm, clear surgical margins (≥ 3 mm)	78.2%	Consensus
VIII. Age 50 years or more	87.0%	Consensus
IX. Unicentric or unifocal	100%	Unanimous consensus
X. Primary systemic therapy and neoadjuvant chemotherapy is considered an exclusion criterion for partial breast irradiation	78.2%	Consensus






pT1-pT2 (< 3 cm)
pN0
R0 (> 2 mm)
SBR1-2
Age > 50 ans
Unifocal
Low grade DCIS

5. Partial breast irradiation—dose and fractionation

5a. Moderate hypofractionation (40 Gy in 15 fractions) and ultrahypofractionation (26–30 Gy in five fractions) represent acceptable schedules for external beam partial breast irradiation	91.6%	Strong consensus
5b. Twice a day external beam partial breast irradiation dose and fractionations similar to those used in the RAPID trial should not be offered	86.9%	Consensus






Example



Can brachytherapy be an alternative ?

- What is brachytherapy ?
 - ➔ Placement of radioactive material, either temporarily or permanently, directly inside the body in order to treat cancer
 - ➔ unlike external beam radiotherapy, that delivers radiation through healthy tissues, brachytherapy delivers dose directly within or adjacent to tumor

Can brachytherapy be an alternative ?



- Thank you for your attention



Waisse.waissi@lyon.unicancer.fr